• Explore /
  • Poster
  • / Phase I/II study to evaluate the efficacy of TAS0313, a cancer peptide vaccine, combined with pembrolizumab for locally advanced or metastatic urothelial carcinoma.

Phase I/II study to evaluate the efficacy of TAS0313, a cancer peptide vaccine, combined with pembrolizumab for locally advanced or metastatic urothelial carcinoma.

Abstract Video & Slides Poster

Authors

null

Ryuji Matsumoto

Department of Renal and Genitourinary Surgery, Hokkaido University, Sapporo, Japan

Ryuji Matsumoto , Junji Yonese , Takashi Kawahara , Hideaki Miyake , Nobuaki Matsubara , Hiroji Uemura , Masatoshi Eto , Haruhito Azuma , Wataru Obara , Akito Terai , Satoshi Fukasawa , Shigetaka Suekane , Hiroyuki Nishiyama

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Bladder Cancer

Clinical Trial Registration Number

183824

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 4522)

DOI

10.1200/JCO.2021.39.15_suppl.4522

Abstract #

4522

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Karim Amrane Sr.

Poster

2023 ASCO Annual Meeting

Phase II study of pembrolizumab plus mifepristone in patients with advanced HER2-negative breast cancer.

Phase II study of pembrolizumab plus mifepristone in patients with advanced HER2-negative breast cancer.

First Author: Nan Chen

First Author: Katharine Andress Rowe Price

First Author: Alexandra Leary